2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2525

Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Abstract Number: 110

Patient Decisions Related to Hip and Knee Arthroplasty and the Factors Influencing Them
Abstract Number: 456

Patient Engagement in Research: Understanding Patient Interest and Needs
Abstract Number: 541

Patient Goals in Rheumatoid Arthritis Care: A Literature Review
Abstract Number: 2951

Patient Outcomes in Primary Angiitis of the Central Nervous System
Abstract Number: 2921

Patient Participation in Patient Reported Outcome Instrument Development in Systemic Sclerosis
Abstract Number: 224

Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Abstract Number: 3189

Patient Perceptions of Glucocorticoid Side Effects: A Survey of Users in an Online Health Community
Abstract Number: 2373

Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Abstract Number: 2649

Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Abstract Number: 2173

Patient Reported Disease Activity and Efficacy of Biologic Therapy in Patients with Psoriatic Arthritis. an Observational Study of 107 Patients of the Estonian Society for Rheumatology Biologic Therapy Register during 2008-2014
Abstract Number: 106

Patient Satisfaction Survey of a Newly Set up Physiotherapist Lead Axial Spondyloarthritis Clinic
Abstract Number: 100

Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Abstract Number: 2644

Patient Survey Regarding Generic and Bio-Similar Drugs
Abstract Number: 2530

Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].